One of the key findings was the discovery of a potent and specific beneficial effect of PARP inhibition in BRCA2-deficient tumours, due to the defect in homologous recombination repair (HRR) in the BRCA2-deficient cells [64, 65]. This evidence concerns the gene BRCA2 and neoplasm.